BRAF and neoplasm: Although BRAF inhibition can enhance antigen expression, facilitates T-cell cytotoxicity, and creates a favorable tumor microenvironment, potentially augmenting the efficacy of immunotherapy [86,87,88], recent investigations revealed that resistance to BRAF/MEK inhibitors induces an immune-evasive tumor microenvironment [89,90].